The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.
about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondAnalyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesSimultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancerRituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical responseMechanisms of action of CD20 antibodies.Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.IgA EGFR antibodies mediate tumour killing in vivo.Immunotherapy for B-cell lymphoma: current status and prospective advancesReduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer TherapyAn Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity
P2860
Q26766718-018FBA67-B727-4994-9306-4738CFA58922Q27694769-349698A8-BDC3-477C-AADB-3AB0A54F75A3Q33889191-D9807F7C-C5B0-4EC1-AD63-AC2A1FB80C7CQ36057882-78FED6B3-78E5-436C-91E9-290A5ED0F3DCQ36216264-341BFDD9-1C59-4267-BDDE-4C1DD71A8B07Q38066195-FA8BF773-1760-4E67-B43F-8EB651A6E7D3Q38291696-F2351989-AA62-41C0-B96C-D3985D4C57E6Q38530254-80ADED2F-924B-49DA-A6C9-F0F8B1227950Q38542034-33875027-8537-4504-B1A3-228B1BBC8E90Q39004366-4756D548-A8A5-4619-801D-419B592FBBC1Q39114924-FD3B599F-A169-427B-9098-484BA689AF90Q41831989-756D3DA7-2568-4AFC-AB29-F4679E95446EQ41966008-D842E50E-6BA6-4C05-9F03-79CC96470BBEQ42660162-5F20E949-193D-4A84-9FF2-4B79FB7B7CBEQ42660174-0C97F13E-3DA6-4A96-8BB7-081956C707F8Q56908538-42AA5EA7-4F12-4F0F-9435-D4D2AF9259D4
P2860
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The in vivo mechanism of actio ...... depends on local tumor burden.
@en
The in vivo mechanism of actio ...... depends on local tumor burden.
@nl
type
label
The in vivo mechanism of actio ...... depends on local tumor burden.
@en
The in vivo mechanism of actio ...... depends on local tumor burden.
@nl
prefLabel
The in vivo mechanism of actio ...... depends on local tumor burden.
@en
The in vivo mechanism of actio ...... depends on local tumor burden.
@nl
P2093
P2860
P50
P1433
P1476
The in vivo mechanism of actio ...... depends on local tumor burden
@en
P2093
Cees E van der Poel
Frank J Beurskens
J H Marco Jansen
Jan G J van de Winkel
Lisette Bevaart
Maaike Nederend
Peter Boross
Simone de Haij
P2860
P304
P356
10.3324/HAEMATOL.2011.047159
P577
2011-08-31T00:00:00Z